{"id":"W4200579141","doi":"10.1007/s40273-021-01106-6","title":"Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne; Hôpital Notre-Dame; Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"Sanofi Genzyme; EMD Serono; Monash University; Novartis Pharma; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; Mylan; Biogen; MedDay Pharmaceuticals; Celgene; Sanofi","keywords":"Fingolimod; Natalizumab; Medicine; Multiple sclerosis; Health economics; Relapsing remitting; Cost effectiveness; Quality of Life Research; Public health; Pharmacoeconomics; Disease; Intensive care medicine; Physical therapy; Immunology; Internal medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00685652,0.0005204292,0.001633659,0.001028204,0.0001539914,0.001388048,0.0007477123,0.001042652,0.002126575],"category_scores_gemma":[0.03494612,0.0003718472,0.002708722,0.001090438,0.0005715234,0.000854075,0.001313311,0.0007503837,0.0001233416],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005146906,"about_ca_system_score_gemma":0.001164329,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01858956,"about_ca_topic_score_gemma":0.01200142,"domain_scores_codex":[0.9892429,0.008503722,0.0008436974,0.000443228,0.0006031772,0.0003632568],"domain_scores_gemma":[0.9872996,0.008364711,0.002849555,0.000412306,0.0005927911,0.0004810417],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2421426,0.001361939,0.4003584,0.01134424,0.03611422,0.001533141,0.00131194,0.1592435,0.00162705,0.005737434,0.004683669,0.1345419],"study_design_scores_gemma":[0.06131503,0.03115403,0.7408304,0.006095307,0.03417942,0.002874658,0.001677563,0.106874,0.002062069,0.004047713,0.008512162,0.0003777332],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9730473,0.02171967,0.0005679851,0.0007040208,0.00008191612,0.0002030695,0.001647182,0.00001143127,0.002017402],"genre_scores_gemma":[0.9979601,0.001109854,0.0002106551,0.00008596259,0.00001050175,0.00006479819,0.000456035,0.000002100937,0.0001000659],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01858956,"threshold_uncertainty_score":0.03734356,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1193435317011464,"score_gpt":0.3735801482993999,"score_spread":0.2542366165982535,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}